Raltegravir
- Generic Name
- Raltegravir
- Brand Names
- Isentress
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN6O5
- CAS Number
- 518048-05-0
- Unique Ingredient Identifier
- 22VKV8053U
- Background
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
- Indication
For the treatment of HIV-1 infection in conjunction with other antiretrovirals.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Post-exposure prophylaxis for occupational exposure to HIV therapy
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
- Conditions
- HIV-1 InfectionTreatment Resistant DisordersViremia
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 4
- Registration Number
- NCT02247687
- Locations
- 🇫🇷
Hôpital Européen Georges Pompidou, France, France
🇫🇷Hôpital Avicenne, Bobigny, France
🇫🇷Hôpital Jean Verdier, Bondy, France
Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2018-12-26
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 20
- Registration Number
- NCT02218320
- Locations
- 🇺🇸
Clinical and Translational Research Center, UNC Hospitals, Chapel Hill, North Carolina, United States
Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 170
- Registration Number
- NCT02212379
- Locations
- 🇫🇷
Hôpital Cochin, Paris, France
🇫🇷Hôpital Necker, Paris, France
🇫🇷Hôpital Croix Rousse, Lyon, France
Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02182375
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
- Conditions
- HIV Infection
- Interventions
- Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)Drug: Lopinavir/Ritonavir (LPV/r)
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2025-04-04
- Target Recruit Count
- 1120
- Registration Number
- NCT02140255
- Locations
- 🇺🇸
4601, University of California, San Diego Clinical Research Site, La Jolla, California, United States
🇺🇸5048, University of Southern California Clinical Research Site, Los Angeles, California, United States
🇺🇸5112, David Geffen School of Medicine at UCLA Clinical Research Site, Los Angeles, California, United States
Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
- Conditions
- HIV Infection
- Interventions
- Drug: TRUVADA™Drug: Placebo to Reformulated Raltegravir
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 802
- Registration Number
- NCT02131233
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02116660
Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2016-09-13
- Lead Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Target Recruit Count
- 11
- Registration Number
- NCT02097108
- Locations
- 🇦🇹
AKH Wien, Wien, Austria
🇦🇹PMU Salzburg, Salzburg, Austria
🇦🇹Ottto Wagner Spital, Wien, Austria
Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa
- Conditions
- HIV Infection
- Interventions
- Behavioral: adherence reinforcement
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 201
- Registration Number
- NCT02025868
- Locations
- 🇧🇫
CHU Yalgado Ouedraogo, Ouagadougou, Burkina Faso
🇧🇫CHU Sourô Sanou, Bobo-Dioulasso, Burkina Faso
🇨🇮Centre de Prise en Charge et de Formation (CePReF), Association ACONDA, Abidjan, Côte D'Ivoire
Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 107
- Registration Number
- NCT01989910
- Locations
- 🇨🇳
Division of Infectious Diseases, Taipei Veterans General Hospital, Taipei, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.